Abstract
AIM: The investigation of the influence of intralesional interleukin-2 (IL-2) on the clinical course and tumor progression in dogs suffering from urinary bladder and urethral carcinomas.
MATERIALS AND METHODS: Medical records of 25 dogs diagnosed with advanced transitional cell carcinomas (TCC) were retrospectively reviewed. In 14 dogs, intralesional IL-2 treatment was performed by transabdominal ultrasound-guided injection. Seven dogs underwent cytoreductive surgery, followed by IL-2 injection into the tumor bed. All dogs received long-term non-steroidal anti-inflammatory drugs.
RESULTS: Adverse effects associated with IL-2 treatment were not observed. At re-examination, 17 dogs showed marked clinical improvement and regression of tumor size. Four dogs were in complete remission.
CONCLUSION: Intralesional IL-2 application is a safe and minimally-invasive palliative treatment option in dogs suffering from advanced transitional cell carcinoma when surgical cure is impossible. Prognosis depends on tumor localization and feasibility of concomitant cytoreductive surgery.
| Original language | English |
|---|---|
| Pages (from-to) | 931-935 |
| Number of pages | 5 |
| Journal | In Vivo |
| Volume | 26 |
| Issue number | 6 |
| Publication status | Published - 20 Nov 2012 |
Keywords
- Canine
- transitional cell carcinoma
- interleukin-2
- urinary
- bladder
- urethral carcinoma